CDXS

Codexis, Inc. (CDXS)
Healthcare • Biotechnology • $2.24 • MCap: 203,608,320 🌐
https://www.codexis.com • Codexis, Inc. provides technology solutions for therapeutics manufacturing, leveraging its proprietary CodeEvolver technology platform to discover, develop, enhance, and commercialize novel enzymes in the United States, Canada, Latin America, Europe, the Middle East, Africa, Australia, New Zealand, Southeast Asia, and China. The company develops its proprietary ECO Synthesis manufacturing platform to enable the scaled manufacture of RNAi therapeutics through an enzymatic route. It has a license agreement with Aldevron LLC and Pfizer Inc. The company was incorporated in 2002 and is headquartered in Redwood City, California.
Buy Decision Core
Total Score
29
Business Quality
4
Financial Strength
10
Growth Outlook
1
Momentum
4
Price Action
Current
2.24
52W High
3.33
52W Low
0.98
Above 50DMA
2.50 (-10.29%)
Above 200DMA
2.02 (11.17%)
Relative Strength
Relative Strength
-0.06
RS 3M
-0.12
RS 6M
0.26
RS 9M
-0.11
RS 12M
-0.21
Fundamentals
Revenue Growth
1.02%
Earnings Growth
0%
ROE
-0.69%
ROA
-0.13%
Valuation
PE (Fwd)
-6.05
PEG
13.53
P/B
4.71
Upside
193.90%
Risk
Beta
2.50
Short %
0.04
Risk Score
7.00
Analyst
Rating
none
Target
6.58
Beta
2.50
Analysts
0
Total Score
29
Upside
193.90%
Relative Strength
-0.06
Beta
2.50
Why Buy?
  • Trading above 200 DMA
  • Analyst upside exceeds 15%
Key Risks
  • Negative ROE
  • High volatility (Beta > 1.5)
  • Weak long-term relative strength
Score Breakdown
Business
4
Financial
10
Growth
1
Valuation
6
Risk
1
Momentum
4
Technical
52W High: 3.33
52W Low: 0.98
Above 50DMA: -10.29%
Above 200DMA: 11.17%
Valuation
Forward PE: -6.05
PEG: 13.53
P/B: 4.71
Upside: 193.90%
Risk
Beta: 2.50
Short Float: 0.04%
ROE: -0.69%
ROA: -0.13%